- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04614415
Clinical Investigation to Evaluate the Performance of Hyaluronic Acid for the Treatment of Hypertrophic Scars
Multicenter, Double Blind, Randomized, Controlled Clinical Investigation to Evaluate the Performance of Autocross-linked Hyaluronic Acid for the Treatment of Hypertrophic Scars
The study includes two study groups, one involves treatment with auto-cross-linked Hyaluronic acid by intralesional and hypodermic injection, repeated after two weeks (T14), while the control arm provides an equal treatment but with isotonic saline solution.
Enrolled patients will be randomized into 2 groups with an allocation of 2:1 in study treatment arm and control arm respectively. They will be evaluated using the POSAS scale before the treatment and re-evaluated at 30, 90 and 180 days after treatment.
The scar evaluation will be completed by an ultrasound assessment at time 0 (T0), 30 (T30), T90 and T180 and the DLQI (Dermatology Life Quality Index) to be assessed at time 0 (T0), 30 (T30), 90 (T90) and 180 (T180).
In subjects that will consent, a small surgical biopsy for an explorative evaluation of the scar tissue will be performed before (T0) and after treatment (T30) for a histological assessment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nicola Giordan
- Phone Number: +39 349 823 2111
- Email: ngiordan@fidiapharma.it
Study Locations
-
-
-
Ancona, Italy
- Recruiting
- AOU Ospedali Riuniti- SOD Chirurgia ricostruttiva e chirurgia della mano
-
Contact:
- Michele Riccio, MD
-
Cesena, Italy
- Recruiting
- U.O. Centro Grandi Ustionati Ospedale Bufalini di Cesena - AUSL
-
Contact:
- Davide Melandri, Dr
-
Parma, Italy
- Not yet recruiting
- U.O.C. Chirurgia Plastica e Centro Ustioni Azienda Ospedaliero-Universitaria di Parma
-
Contact:
- Edoardo Caleffi, Prof.
-
Pisa, Italy
- Not yet recruiting
- U.O.C. Centro Ustioni Azienda Ospedaliero-Universitaria Pisana
-
Contact:
- Antonio Di Lonardo, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed written informed consent
- Male or female subjects aged ≥ 18 and ≤ 85 years
- Subjects with hypertrophic scars caused by trauma, burn or iatrogenic injury with or without involvement of the mobile joints
- Scar > 2 to < 25 cm2 of surface
- Scar not previously treated with corticosteroids, laser or other invasive treatments
- Scar present for at least 12 months
- Scar located in all areas of the body with the exception of the face and neck
- Fitzpatrick skin score of I-VI
- Subjects willing to comply with all the steps of treatment and follow-up visits
- Subjects willing to refrain from any cosmetic intervention in the area to be treated during the clinical investigation
- Female of child-bearing potential (i.e. not in menopausal status from at least one year or permanently sterilized) must have a negative urine pregnancy test prior the first treatment
Exclusion Criteria:
Subjects with type I and type II diabetes mellitus
- Subjects with oncological diseases in progress or in remission
- Subjects receiving immunosuppressive drugs and corticosteroids, anticoagulants, antiplatelet agents
- Subjects with autoimmune diseases including connectivitis
- Subjects with congenital or acquired immunodeficiencies (including metabolic ones)
- Subjects with known allergy or hypersensitivity to hyaluronic acid or its derivatives
- Participation in clinical trials/investigations in the last 30 days
- Pregnant or breastfeeding women
- If female and of child-bearing potential, subject not using a highly effective method of birth control and not willing to use it during the participation to the clinical investigation
- Subjects not willing to avoid tanning during the clinical investigation
- Subjects with inflammations of the skin, including rosacea
- Subject with skin infection in the area to be treated
- Subjects having a high probability of non-compliance with the study procedures according to Investigator's judgement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group
group 1 will be treated with autocrosslinked Hyaluronic acid
|
IAL-SYSTEM ACP gel is an auto-cross-linked HA derivative in the form of highly viscous gel.
In this direct formation of ester linkages no foreign substances are introduced into the molecule, thus catabolism of ACP leads only to HA
Other Names:
|
Placebo Comparator: control group
group 2 treated with placebo (isotonic saline solution).
|
The placebo consists in an isotonic saline solution (NaCl 0.9%)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline to Day 90 in POSAS total score for Observer
Time Frame: 90 days after treatment
|
The performance of two injections of IAL-SYSTEM ACP in improving the quality of the scar after 90 days from the first treatment in patients with hypertrophic scars will be evaluated by the mean change from baseline to Day 90 in POSAS total score for Observer.
|
90 days after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the performance of IAL-SYSTEM ACP in improving the quality of the scar
Time Frame: after 30 and 180 days from the first treatment
|
Change from baseline to post-baseline visits (T30, T90 and T180) in total POSAS scores (sum total of Patient and Observer scores), and POSAS total score for Patient and Observer
|
after 30 and 180 days from the first treatment
|
To assess the changing in the Quality of life after 30, 90 and 180 days from the first treatment with the Dermatology Life Quality Index (DLQI)
Time Frame: after 30, 90 and 180 days from the first treatment
|
Change from baseline to post-baseline visits (T30, T90 and T180) in DLQI score (dermatology quality of life Index)
|
after 30, 90 and 180 days from the first treatment
|
To assess the changing in the dermal volume after 30, 90 and 180 days from the first treatment
Time Frame: after 30, 90 and 180 days
|
Change from baseline to post-baseline visits (T30, T90 and T180) in dermal volume measured by ultrasound
|
after 30, 90 and 180 days
|
Safety of the treatment. Number of patients with treatment related adverse events
Time Frame: throug clinical investigation completion, an average one year
|
Safety evaluation examining the local and systemic adverse effects as consequence of the treatment and any other adverse event occurred during the study.
|
throug clinical investigation completion, an average one year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LQ5I-19-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrophic Scar
-
Iran University of Medical SciencesRecruitingDry Needling | Scar Tissue | Hypertrophic Scar | Hypertrophic Surgical Scar | Hypertrophic Scar of Upper Arm (Disorder)United States, Iran, Islamic Republic of
-
University of PittsburghUnited States Department of DefenseTerminatedBurn Scar | Restrictive Scar Contracture | Restrictive Hypertrophic Scar | Burn Scar ContracturesUnited States
-
Nova Scotia Health AuthorityRecruiting
-
Henry Ford Health SystemActive, not recruitingScar | Hypertrophic ScarUnited States
-
Universiti Kebangsaan Malaysia Medical CentreCompletedKeloid Scar Following Surgery | Caesarean Wound | Hypertrophic Surgical ScarMalaysia
-
Medstar Health Research InstituteCompletedBurn Scar | Hyperpigmentation | Hypertrophic Scar | Hypopigmented ScarUnited States
-
PfizerTerminatedHypertrophic Scars Resulting From Prior Breast Scar Revision SurgeryUnited States
-
Dr.dr.Irma Bernadette, SpKK (K)Not yet recruitingBurn Scar | Scars, HypertrophicIndonesia
-
Seoul National University HospitalCompletedHypertrophic Surgical ScarKorea, Republic of
-
Kaohsiung Medical UniversityUnknown
Clinical Trials on Autocrosslinked Hyaluronic aid
-
Northwestern UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)Completed
-
Sonova AGCompletedHearing Loss, Sensorineural | Hearing Loss, BilateralCanada
-
NorthShore University HealthSystemCompletedCognitive AidsUnited States
-
Massachusetts General HospitalCompletedCoronary Artery Disease | Stable AnginaUnited States
-
Bernafon AGCompletedHearing LossSwitzerland
-
University of LeedsBaxter Healthcare Corporation; National Health Service, United Kingdom; Foundation... and other collaboratorsCompletedChronic Kidney FailureUnited Kingdom
-
Case Comprehensive Cancer CenterCompletedProstate CancerUnited States
-
Duke UniversityFoundation for Informed Medical Decision MakingCompletedOsteoarthritisUnited States
-
University Hospital HeidelbergInnovationsfonds des Gemeinsamen Bundesausschusses, GermanyCompletedPatient Decision Aid | Treatment As UsualGermany
-
Massachusetts General HospitalUnknownDecision Making | Video Decision AidsUnited States